Sarepta Therapeutics, Inc. (LON:0L35)
 23.56
 -0.76 (-3.13%)
  At close: Nov 3, 2025
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $611.09M USD in the quarter ending June 30, 2025, with 68.38% growth. This brings the company's revenue in the last twelve months to $2.48B, up 64.89% year-over-year. In the year 2024, Sarepta Therapeutics had annual revenue of $1.90B with 52.97% growth.
Revenue (ttm) 
 $2.48B
Revenue Growth 
 +64.89%
P/S Ratio 
 1.00
Revenue / Employee 
 $1.81M
Employees 
 1,372
Market Cap 
1.82B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 1.90B | 658.64M | 52.97% | 
| Dec 31, 2023 | 1.24B | 310.32M | 33.26% | 
| Dec 31, 2022 | 933.01M | 231.13M | 32.93% | 
| Dec 31, 2021 | 701.89M | 161.79M | 29.96% | 
| Dec 31, 2020 | 540.10M | 159.27M | 41.82% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| AstraZeneca | 41.24B | 
| GSK plc | 32.17B | 
| Haleon | 11.02B | 
| Smith & Nephew | 4.33B | 
| Hikma Pharmaceuticals | 2.35B | 
| ConvaTec Group | 1.72B | 
| Spire Healthcare Group | 1.55B | 
| Genus | 672.80M | 
Sarepta Therapeutics News
- 3 days ago - A Peek at Sarepta Therapeutics's Future Earnings - Benzinga
 - 4 days ago - Piper Sandler Maintains Neutral Rating on SRPT, Raises Price Target to $16 | SRPT Stock News - GuruFocus
 - 4 days ago - Interesting SRPT Put And Call Options For December 19th - Nasdaq
 - 7 days ago - Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results - Business Wire
 - 11 days ago - Tradr Launches 9 Single-Stock 2X ETFs With First-Of-Its-Kind OpenDoor, Gold And AI Exposure - Benzinga
 - 11 days ago - Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF - PRNewsWire
 - 24 days ago - Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline - Seeking Alpha
 - 26 days ago - What's Going On Sarepta Stock On Wednesday? - Benzinga